Benchmark Genetics has appointed Thomas Samdal as its new Chief Financial Officer, effective 1 April. He joins the company’s executive management team, succeeding Jon Crowther, who will retire following a short transition period.
“Benchmark Genetics plays a key role in the global aquaculture value chain, where genetics is the starting point for both sustainability and profitability. I am motivated by the opportunity to contribute to a more efficient and sustainable food system. At the same time, it is very exciting to join the company at this stage, where we will continue to develop and scale the business. An important part of my role will be to ensure that the finance function actively supports the core business and enables the organisation to achieve its strategic goals”, said Samdal.
Samdal joins from NORCE, where he served as CFO with responsibility for the group’s finance function, including reporting, financing, sustainability reporting and other corporate areas. He has previously held CFO roles in several companies and brings experience in investment activities and auditing.
He holds a Master of Science in Economics and Business Administration from the Norwegian School of Economics, as well as a Master’s degree in Accounting and Auditing. With nearly 20 years of experience in auditing, corporate finance and financial leadership, he brings a strong combination of financial expertise and operational insight, alongside extensive private equity experience both as an Investment Manager and as CFO in PE-backed companies.
“We are very pleased to welcome Thomas to the team. He brings a strong professional profile and broad experience from both commercial companies and research environments. This combination fits very well with Benchmark Genetics as we continue to build on our position as a global leader in aquaculture genetics. His ability to connect strategy with operational execution will be important for the company’s continued development”, said CEO Kristian Botnen.
Over the past year, Benchmark Genetics has established itself as an independent company under the ownership of Novo Holdings, with a clear strategy for further growth in genetics and genotyping services globally.
